Exploitation of protein kinase C: A useful target for cancer therapy

被引：98

作者：

Ali, Ashhar S. ^{[1
]}

Ali, Shadan ^{[2
]}

El-Rayes, Basset F. ^{[2
]}

Philip, Philip A. ^{[2
]}

Sarkar, Fazlul H. ^{[1
]}

机构：

[1] Wayne State Univ, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA

[2] Wayne State Univ, Karmanos Canc Inst, Dept Hematol & Oncol, Detroit, MI 48201 USA

来源：

CANCER TREATMENT REVIEWS | 2009年 / 35卷 / 01期

关键词：

PKC isoenzymes; Invasion; Metastasis; HUMAN HEPATOCELLULAR-CARCINOMA; HUMAN COLON-CANCER; PROMOTING PHORBOL ESTERS; PHASE-II TRIAL; BREAST-CANCER; INDUCED APOPTOSIS; GROWTH-FACTOR; PKC-EPSILON; CELL-CYCLE; ANTISENSE OLIGONUCLEOTIDE;

D O I：

10.1016/j.ctrv.2008.07.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Protein kinase C is a family of serine/threonine kinases. The PKC family is made up of at least 12 isozymes, which have a rote in cell proliferation, differentiation, angiogenesis, and apoptosis. Activation of PKC isozyme is dependent on tyrosine-kinase receptors and G-protein-coupled receptors. PKC isozymes regulate multiple signaling pathways including PI3-K/Akt, MAPK, and GSK-3 beta. PKC isozymes have variable roles in tumor biology which in part depend on the cell type and intracellular localization. PKC isozymes are commonly dysregulated in the cancer of the prostate, breast, colon, pancreatic, liver, and kidney. Currently, several classes of PKC inhibitors are being evaluated in clinical trials and several challenges in targeting PKC isozymes have been recently identified. In conclusion, PKC remains a promising target for cancer prevention and therapy. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：1 / 8

页数：8

共 88 条

[1] A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21-day infusion to patients with advanced ovarian carcinoma [J].

Advani, R ;

Peethambaram, P ;

Lum, BL ;

Fisher, GA ;

Hartmann, L ;

Long, HJ ;

Halsey, J ;

Holmlund, JT ;

Dorr, A ;

Sikic, BI .

CANCER, 2004, 100 (02) :321-326

[2] Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: A north central cancer treatment group phase II trial [J].

Alberts, SR ;

Schroeder, M ;

Erlichman, C ;

Steen, PD ;

Foster, NR ;

Moore, DF ;

Rowland, KM ;

Nair, S ;

Tschetter, LK ;

Fitch, TR .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (24) :4944-4950

[3] Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1 [J].

Ali, S ;

Aranha, O ;

Li, YW ;

Pettit, GR ;

Sarkar, FH ;

Philip, PA .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (03) :235-246

[4] Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer [J].

Assender, J. W. ;

Gee, J. M. W. ;

Lewis, I. ;

Ellis, I. O. ;

Robertson, J. F. R. ;

Nicholson, R. I. .

JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (11) :1216-1221

[5]

Assert R, 1999, INT J CANCER, V80, P47, DOI 10.1002/(SICI)1097-0215(19990105)80:1<47::AID-IJC10>3.3.CO

[6]

2-A

[7] Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms [J].

Balendran, A ;

Hare, GR ;

Kieloch, A ;

Williams, MR ;

Alessi, DR .

FEBS LETTERS, 2000, 484 (03) :217-223

[8] Neuroprotective effects of natural products: Interaction with intracellular kinases, amyloid peptides and a possible role for transthyretin [J].

Bastianetto, Stephane ;

Brouillette, Jonathan ;

Quirion, Remi .

NEUROCHEMICAL RESEARCH, 2007, 32 (10) :1720-1725

[9] Protein kinase C-mediated regulation of the cell cycle [J].

Black, JD .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2000, 5 :D406-D423

[10]

Brenner W, 2004, INT J ONCOL, V25, P1157

← 1 2 3 4 5 6 7 8 9 →